Local Institution - 0061
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
8 recruiting
Showing 1–15 of 15 trials
Recruiting
Phase 2
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Solid Tumors
Bristol-Myers Squibb260 enrolled57 locationsNCT07492680
Recruiting
Phase 2Phase 3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb590 enrolled318 locationsNCT07063745
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Advanced Renal Cell Carcinoma (RCC)
Bristol-Myers Squibb474 enrolled91 locationsNCT07293351
Recruiting
Phase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Multiple Sclerosis Spasticity
Celgene200 enrolled54 locationsNCT06782490
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
Schizophrenia
Bristol-Myers Squibb166 enrolled39 locationsNCT07288567
Recruiting
Phase 3
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
Renal Allograft Recipients
Bristol-Myers Squibb102 enrolled38 locationsNCT04877288
Recruiting
Phase 3
A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively
SchizophreniaAutism-Related Irritability
Karuna Therapeutics, Inc., a Bristol Myers Squibb company400 enrolled95 locationsNCT07424404
Recruiting
Phase 2Phase 3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Non-small Cell Lung Cancer
Bristol-Myers Squibb500 enrolled186 locationsNCT07100080
Recruiting
Phase 1Phase 2
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
Arthritis, Rheumatoid
Bristol-Myers Squibb84 enrolledNCT07412704
Recruiting
Phase 3
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
Juvenile Psoriatic Arthritis
Bristol-Myers Squibb60 enrolled47 locationsNCT06869551
Recruiting
Phase 1Phase 2
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
Healthy VolunteersAnemia, Sickle Cell
Bristol-Myers Squibb224 enrolled33 locationsNCT06481306
Recruiting
Phase 2
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Solid Tumors
Mirati Therapeutics Inc.170 enrolled101 locationsNCT07415031
Recruiting
Phase 2
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
Lupus Erythematosus, SystemicLupus Nephritis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company89 enrolled96 locationsNCT07015983
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
Systemic Sclerosis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company92 enrolled56 locationsNCT07335562
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Follicular Lymphoma
Celgene400 enrolled160 locationsNCT06911502